- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05767645
Mistral Percutaneous Tricuspid Valve Durable Repair Pivotal Study (TRIBUTE)
The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).
The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objectives of this study are to evaluate safety and effectiveness of the Mistral implant for the percutaneous treatment of patients with symptomatic moderate or greater tricuspid regurgitation (TR) who are at high risk for tricuspid valve surgery.
Primary endpoints:
- Safety: Incidence of Major Device Related Adverse Events (MDRAE). [Time frame: 6 months].
- Efficacy: Echocardiographic improvement in TR severity of at least 1 grade [Time Frame: 30 days].
Secondary endpoints:
Safety:
- Incidence of Major Device Related Adverse Events (MDRAE). [Time Frame: 1, 6, 12, and 24 months].
- Incidence of device or procedure related serious adverse events [Time Frame: 30 days].
Efficacy:
• Change in TR grade by Echocardiography [Time Frame: 1, 6, 12, and 24 months over baseline].
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dana Yaron
- Phone Number: +972542330022
- Email: dana@mitralix.com
Study Contact Backup
- Name: Ira Yaron
- Phone Number: +972544402636
- Email: ira@mitralix.com
Study Locations
-
-
-
H̱olon, Israel
- Recruiting
- Wolfson Medical Center
-
Contact:
- Mary Israelson
- Phone Number: +97235028699
- Email: MaryI@wmc.gov.il
-
Principal Investigator:
- Ronen Rubinshtein
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is able and willing to give informed consent, follow protocol procedures, and comply with follow-up visit requirements
- Subject is ≥ 18 years of age or legal age in host country
Minimum of moderate functional or degenerative tricuspid regurgitation:
- Subjects with moderate TR: Only NYHA (New York Heart Association) Class III or IV maybe considered for inclusion.
- Subjects with severe or greater TR: NYHA (New York Heart Association) Class II, III, or IV may be considered for inclusion
- Subject has left ventricular ejection fraction (LVEF) >20 %
- The subject is at high risk of mortality with tricuspid valve surgery as determined by the cardiac surgeon and an interventional cardiologist at the site (center heart team).
- Femoral or Jugular access of the Steerable Catheter with MDS (Mistral Delivery System) is determined to be feasible.
- Subject must agree not to start participating in any other clinical trial for a period of 6 months following the index procedure.
- As determined by the center heart team, the Mistral is the suitable treatment option.
Exclusion Criteria:
- Tricuspid Stenosis >mild
- Tricuspid Sub valvular calcification or calcification of the chordae.
- Subjects with Mitral valve severe stenosis and/or severe regurgitation.
- Previous tricuspid valve repair or replacement that would interfere with placement of Mistral
- Subjects with severe, uncontrolled hypertension.
- Subjects, which need to undergo an emergency surgery.
- Subject is currently participating in another clinical trial that has not yet completed its primary endpoints.
- Subject has a history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 30 days.
- Subject has a history of a myocardial infarction (MI) in the past 30 days.
- Subject has had a percutaneous coronary intervention (PCI), within the last 30 days before procedure.
- Subject with active endocarditis.
- Subject has echocardiographic evidence of intra-cardiac mass, thrombus, vegetation or soft-mobile deposits.
- Subject has hemodynamic instability requiring inotropic or mechanical support.
- Subject has a known hypersensitivity or contraindication to anticoagulant and antiplatelet medication.
- Subject is on chronic dialysis.
- Bleeding disorders or hypercoagulable state.
- In the judgment of the Investigator, co-morbid condition(s) that could limit the subject's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study.
- Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding.
- Subject has a known allergy to Nitinol alloys, 316L\304 stainless steel.
- Pregnant or lactating women.
- Patients being dependent upon the sponsor or upon the investigator or upon the investigational site.
- According to investigator on site the patient is suffering from a severe end stage disease (e.g. malignancy, severe pulmonary disease, liver disease, renal failure).
- Contraindication for TEE (transesophageal echocardiography) including trans-gastric views.
- Life expectancy of less than 1 year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mistral device
The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR). The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators. |
The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR). The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
• Safety
Time Frame: 6 months
|
Incidence of Major Device Related Adverse Events (MDRAE).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety - Incidence of Major Device Related Adverse Events
Time Frame: 1, 6, 12, and 24 months
|
Incidence of Major Device Related Adverse Events (MDRAE).
|
1, 6, 12, and 24 months
|
Safety - Incidence of device or procedure related serious adverse events
Time Frame: 30 days
|
Incidence of device or procedure related serious adverse events
|
30 days
|
Effectiveness TR
Time Frame: 1, 6, 12, and 24 months over baseline
|
• Change in TR grade by Echocardiography
|
1, 6, 12, and 24 months over baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ronen Rubinshtein, Wolfson
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-1048
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tricuspid Valve Regurgitation
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health... and other collaboratorsActive, not recruitingTricuspid Regurgitation | Mild Tricuspid Regurgitation | Moderate Tricuspid RegurgitationUnited States, Canada, Germany
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedMitral Valve Regurgitation | Tricuspid Valve Regurgitation, Non-rheumaticUnited States
-
Azienda Ospedaliero, Universitaria PisanaNot yet recruitingSevere Tricuspid Valve Regurgitation
-
Michele De BonisCompleted
-
4Tech Cardio Ltd.CompletedTricuspid RegurgitationGermany, France, Italy, Netherlands
-
TriFlo Cardiovascular, Inc.Not yet recruitingSymptomatic Severe Tricuspid RegurgitationItaly
-
IRCCS Policlinico S. DonatoRecruitingTricuspid Regurgitation CongenitalItaly
-
Heart Center Leipzig - University HospitalRecruitingFunctional Tricuspid RegurgitationGermany
-
University of ZurichRecruitingSevere Tricuspid RegurgitationSwitzerland
-
P+F Products + Features GmbHCompletedSevere Tricuspid RegurgitationLithuania
Clinical Trials on Mistral Procedure
-
MitralixCompletedMitral Valve RegurgitationBelgium
-
MitralixCompletedTricuspid Valve RegurgitationGermany
-
MitralixCompletedTricuspid Valve RegurgitationIsrael
-
Hacettepe UniversityCompletedTemperature Change, BodyTurkey
-
University of GöttingenUZ Gent, Belgium; Policlinica de Guipuzcoa, San Sebastian, SpainCompletedPerioperative HypothermiaBelgium, Germany, Spain
-
Minia UniversityCompletedVisual Impairment | IOP DecreasedEgypt
-
University Hospital, ToulouseCompletedTobacco Use DisorderFrance
-
Major Extremity Trauma Research ConsortiumCompleted
-
CathVision ApSTRIQ GROUP Wherry & Klaffke GbRCompletedCardiac ArrhythmiaDenmark, Czechia
-
NYU Langone HealthCompleted